Literature DB >> 20586797

Prevention of spontaneous bleeding in dogs with haemophilia A and haemophilia B.

T C Nichols1, R A Raymer, H W G Franck, E P Merricks, D A Bellinger, N DeFriess, P Margaritis, V R Arruda, M A Kay, K A High.   

Abstract

Dogs with haemophilia A or haemophilia B exhibit spontaneous bleeding comparable with the spontaneous bleeding phenotype that occurs in humans with severe haemophilia. The phenotypic and genotypic characteristics of haemophilic dogs have been well-described, and such dogs are suitable for testing prophylactic protein replacement therapy and gene transfer strategies. In dogs with haemophilia, long-term effects on spontaneous bleeding frequency (measured over years) can be used as an efficacy endpoint in such studies. Although complete correction of coagulopathy has not been achieved, published data show that prophylactic factor replacement therapy and gene transfer can markedly reduce the frequency of spontaneous bleeding in haemophilic dogs. Further studies are currently ongoing.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20586797      PMCID: PMC3101869          DOI: 10.1111/j.1365-2516.2010.02255.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  30 in total

1.  Two distinct mutations cause severe hemophilia B in two unrelated canine pedigrees.

Authors:  W Gu; M Brooks; J Catalfamo; J Ray; K Ray
Journal:  Thromb Haemost       Date:  1999-10       Impact factor: 5.249

2.  Aberrant splicing and premature termination of transcription of the FVIII gene as a cause of severe canine hemophilia A: similarities with the intron 22 inversion mutation in human hemophilia.

Authors:  Christine Hough; Seiki Kamisue; Cherie Cameron; Colleen Notley; Shawn Tinlin; Alan Giles; David Lillicrap
Journal:  Thromb Haemost       Date:  2002-04       Impact factor: 5.249

3.  Characteristic mRNA abnormality found in half the patients with severe haemophilia A is due to large DNA inversions.

Authors:  J Naylor; A Brinke; S Hassock; P M Green; F Giannelli
Journal:  Hum Mol Genet       Date:  1993-11       Impact factor: 6.150

4.  The Chapel Hill hemophilia A dog colony exhibits a factor VIII gene inversion.

Authors:  Jay N Lozier; Amalia Dutra; Evgenia Pak; Nan Zhou; Zhili Zheng; Timothy C Nichols; Dwight A Bellinger; Marjorie Read; Richard A Morgan
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-19       Impact factor: 11.205

5.  Reduced bleeding events with subcutaneous administration of recombinant human factor IX in immune-tolerant hemophilia B dogs.

Authors:  Karen E Russell; Eva H N Olsen; Robin A Raymer; Elizabeth P Merricks; Dwight A Bellinger; Marjorie S Read; Bonita J Rup; James C Keith; Kyle P McCarthy; Robert G Schaub; Timothy C Nichols
Journal:  Blood       Date:  2003-08-21       Impact factor: 22.113

6.  Inversions disrupting the factor VIII gene are a common cause of severe haemophilia A.

Authors:  D Lakich; H H Kazazian; S E Antonarakis; J Gitschier
Journal:  Nat Genet       Date:  1993-11       Impact factor: 38.330

7.  Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1.

Authors:  Valder R Arruda; Joerg Schuettrumpf; Roland W Herzog; Timothy C Nichols; Nancy Robinson; Yasmin Lotfi; Federico Mingozzi; Weidong Xiao; Linda B Couto; Katherine A High
Journal:  Blood       Date:  2003-09-11       Impact factor: 22.113

Review 8.  Preclinical pharmacology of albumin-free B-domain deleted recombinant factor VIII.

Authors:  Kenneth Brinkhous; Helena Sandberg; Lars Widlund; Marjorie Read; Timothy Nichols; Jeffery Sigman; Ulla Oswaldsson; Robert G Schaub; Marianne Mikaelsson
Journal:  Semin Thromb Hemost       Date:  2002-06       Impact factor: 4.180

Review 9.  Molecular genetics of coagulation factor VIII gene and hemophilia A.

Authors:  S E Antonarakis
Journal:  Thromb Haemost       Date:  1995-07       Impact factor: 5.249

10.  Canine hemophilia B resulting from a point mutation with unusual consequences.

Authors:  J P Evans; K M Brinkhous; G D Brayer; H M Reisner; K A High
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

View more
  13 in total

1.  Improved kinetics of rIX-FP, a recombinant fusion protein linking factor IX with albumin, in cynomolgus monkeys and hemophilia B dogs.

Authors:  M W Nolte; T C Nichols; J Mueller-Cohrs; E P Merricks; I Pragst; S Zollner; G Dickneite
Journal:  J Thromb Haemost       Date:  2012-08       Impact factor: 5.824

Review 2.  State-of-the-art gene-based therapies: the road ahead.

Authors:  Mark A Kay
Journal:  Nat Rev Genet       Date:  2011-04-06       Impact factor: 53.242

3.  AAV liver expression of FIX-Padua prevents and eradicates FIX inhibitor without increasing thrombogenicity in hemophilia B dogs and mice.

Authors:  Julie M Crudele; Jonathan D Finn; Joshua I Siner; Nicholas B Martin; Glenn P Niemeyer; Shangzhen Zhou; Federico Mingozzi; Clinton D Lothrop; Valder R Arruda
Journal:  Blood       Date:  2015-01-07       Impact factor: 22.113

Review 4.  Animal models of hemophilia.

Authors:  Denise E Sabatino; Timothy C Nichols; Elizabeth Merricks; Dwight A Bellinger; Roland W Herzog; Paul E Monahan
Journal:  Prog Mol Biol Transl Sci       Date:  2012       Impact factor: 3.622

5.  Anti-factor IXa/X bispecific antibody ACE910 prevents joint bleeds in a long-term primate model of acquired hemophilia A.

Authors:  Atsushi Muto; Kazutaka Yoshihashi; Minako Takeda; Takehisa Kitazawa; Tetsuhiro Soeda; Tomoyuki Igawa; Zenjiro Sampei; Taichi Kuramochi; Akihisa Sakamoto; Kenta Haraya; Kenji Adachi; Yoshiki Kawabe; Keiji Nogami; Midori Shima; Kunihiro Hattori
Journal:  Blood       Date:  2014-10-01       Impact factor: 22.113

6.  Gene therapy: the promise of a permanent cure.

Authors:  Christopher D Porada; Christopher Stem; Graca Almeida-Porada
Journal:  N C Med J       Date:  2013 Nov-Dec

7.  Sensitivity of whole blood clotting time and activated partial thromboplastin time for factor IX: relevance to gene therapy and determination of post-transfusion elimination time of canine factor IX in hemophilia B dogs.

Authors:  T C Nichols; H W G Franck; C T Franck; N De Friess; R A Raymer; E P Merricks
Journal:  J Thromb Haemost       Date:  2012-03       Impact factor: 5.824

8.  Portal vein delivery of viral vectors for gene therapy for hemophilia.

Authors:  Alexandra Sherman; Alexander Schlachterman; Mario Cooper; Elizabeth P Merricks; Robin A Raymer; Dwight A Bellinger; Roland W Herzog; Timothy C Nichols
Journal:  Methods Mol Biol       Date:  2014

9.  Lessons Learned from Animal Models of Inherited Bleeding Disorders.

Authors:  Timothy C Nichols
Journal:  Hematol Educ       Date:  2014-06

10.  Muscle Gene Therapy for Hemophilia.

Authors:  Denise E Sabatino; Valder R Arruda
Journal:  J Genet Syndr Gene Ther       Date:  2012-05-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.